Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled- and targeted-release oral solid dosage drugs, today announced that it entered into securities purchase agreements with certain institutional investors providing for the purchase and sale of 5,833,334 common shares at a purchase price of US$0.60 per share in a registered direct offering, resulting in total gross proceeds of approximately US$3.5 million.
IAMGOLD Corporation ("IAMGOLD" or the "Company") today announced it has filed a preliminary short form base shelf prospectus with the securities regulators in each province and territory of Canada, except for the Province of Quebec, and a corresponding registration statement with the United States Securities and Exchange Commission.